Common Contracts
3 similar Equity Underwriting Agreement contracts by Unitil Corp, Vascular Biogenics Ltd.
2,500,000 Ordinary Shares Vascular Biogenics Ltd. EQUITY UNDERWRITING AGREEMENTEquity Underwriting Agreement • November 20th, 2017 • Vascular Biogenics Ltd. • Pharmaceutical preparations • New York
Vascular Biogenics Ltd., an Israeli company (the “Company”), proposes to sell to the several underwriters (the “Underwriters”) named on Schedule I hereto for whom you are acting as the representative (the “Representative”) an aggregate of 2,500,000 shares (the “Shares”) of the Company’s ordinary shares, NIS 0.01 nominal value (the “Ordinary Shares”). The amount of the Shares to be so purchased by the several Underwriters are set forth opposite their names on Schedule I hereto.
2,400,000 Shares Unitil Corporation Common Stock (No Par Value) EQUITY UNDERWRITING AGREEMENTEquity Underwriting Agreement • May 14th, 2012 • Unitil Corp • Electric & other services combined • New York
Unitil Corporation, a New Hampshire corporation (the “Company”), proposes to sell to the several underwriters (the “Underwriters”) named in Schedule I hereto for whom you are acting as representative (the “Representative”) an aggregate of 2,400,000 shares (the “Firm Securities”) of the Company’s common stock, no par value (“Common Stock”). The respective amounts of the Firm Securities to be so purchased by the several Underwriters are set forth opposite their names in Schedule I hereto. The Company also proposes to sell to the Underwriters, at the Underwriters’ option, an aggregate of up to 360,000 additional shares of Common Stock (the “Option Securities”) as set forth below.
2,400,000 Shares Unitil Corporation Common Stock (No Par Value) EQUITY UNDERWRITING AGREEMENTEquity Underwriting Agreement • May 27th, 2009 • Unitil Corp • Electric & other services combined • New York
Unitil Corporation, a New Hampshire corporation (the “Company”), proposes to sell to the several underwriters (the “Underwriters”) named in Schedule I hereto for whom you are acting as representative (the “Representative”) an aggregate of 2,400,000 shares (the “Firm Securities”) of the Company’s common stock, no par value (“Common Stock”). The respective amounts of the Firm Securities to be so purchased by the several Underwriters are set forth opposite their names in Schedule I hereto. The Company also proposes to sell to the Underwriters, at the Underwriters’ option, an aggregate of up to 360,000 additional shares (the “Option Securities”) of the Common Stock as set forth below.
